Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder | Health Disparities | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Epstein  RA, Bobo  WV, Martin  PR,  et al.  Increasing pregnancy-related use of prescribed opioid analgesics.   Ann Epidemiol. 2013;23(8):498-503. doi:10.1016/j.annepidem.2013.05.017 PubMedGoogle ScholarCrossref
2.
Desai  RJ, Hernandez-Diaz  S, Bateman  BT, Huybrechts  KF.  Increase in prescription opioid use during pregnancy among Medicaid-enrolled women.   Obstet Gynecol. 2014;123(5):997-1002. doi:10.1097/AOG.0000000000000208 PubMedGoogle ScholarCrossref
3.
Patrick  SW, Schumacher  RE, Benneyworth  BD, Krans  EE, McAllister  JM, Davis  MM.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.   JAMA. 2012;307(18):1934-1940. doi:10.1001/jama.2012.3951 PubMedGoogle ScholarCrossref
4.
Villapiano  NL, Winkelman  TN, Kozhimannil  KB, Davis  MM, Patrick  SW.  Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013.   JAMA Pediatr. 2017;171(2):194-196. doi:10.1001/jamapediatrics.2016.3750 PubMedGoogle ScholarCrossref
5.
Krans  EE, Patrick  SW.  Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic.   Obstet Gynecol. 2016;128(1):4-10. doi:10.1097/AOG.0000000000001446 PubMedGoogle ScholarCrossref
6.
Ko  JY, Patrick  SW, Tong  VT, Patel  R, Lind  JN, Barfield  WD.  Incidence of neonatal abstinence syndrome—28 states, 1999-2013.   MMWR Morb Mortal Wkly Rep. 2016;65(31):799-802. doi:10.15585/mmwr.mm6531a2 PubMedGoogle ScholarCrossref
7.
Tolia  VN, Patrick  SW, Bennett  MM,  et al.  Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs.   N Engl J Med. 2015;372(22):2118-2126. doi:10.1056/NEJMsa1500439 PubMedGoogle ScholarCrossref
8.
Patrick  SW, Davis  MM, Lehmann  CU, Cooper  WO.  Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012.   J Perinatol. 2015;35(8):650-655. Published correction appears in J Perinatol. 2015;35(8):667. doi:10.1038/jp.2015.36PubMedGoogle ScholarCrossref
9.
ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine.  ACOG Committee opinion no. 524: opioid abuse, dependence, and addiction in pregnancy.   Obstet Gynecol. 2012;119(5):1070-1076. doi:10.1097/AOG.0b013e318256496e PubMedGoogle ScholarCrossref
10.
Fullerton  CA, Kim  M, Thomas  CP,  et al.  Medication-assisted treatment with methadone: assessing the evidence.   Psychiatr Serv. 2014;65(2):146-157. doi:10.1176/appi.ps.201300235 PubMedGoogle ScholarCrossref
11.
Substance Abuse and Mental Health Services Administration.  Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No (SMA) 18-5054. Substance Abuse and Mental Health Services Administration; 2018.
12.
Short  VL, Hand  DJ, MacAfee  L, Abatemarco  DJ, Terplan  M.  Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.   J Subst Abuse Treat. 2018;89:67-74. doi:10.1016/j.jsat.2018.04.003 PubMedGoogle ScholarCrossref
13.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder; Mancher M, Leshner AI, eds. Medications for Opioid Use Disorder Save Lives. National Academies Press (US); 2019.
14.
Substance Abuse and Mental Health Services Administration.  Results From the 2017 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration; 2018.
15.
Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) state instruction manual with State TEDS Submission System. (STSS) guide. Substance Abuse and Mental Health Administration; 2014.
16.
US Department of Health and Human Services. State standards for access to care in Medicaid manged care. Published September 2014. Accessed April 8, 2017. https://oig.hhs.gov/oei/reports/oei-02-11-00320.pdf
17.
US Department of Health and Human Services. Access to care: provider availability in Medicaid managed care. Published December 2014. Accessed April 8, 2017. https://oig.hhs.gov/oei/reports/oei-02-13-00670.pdf
18.
Polsky  D, Richards  M, Basseyn  S,  et al.  Appointment availability after increases in Medicaid payments for primary care.   N Engl J Med. 2015;372(6):537-545. doi:10.1056/NEJMsa1413299 PubMedGoogle ScholarCrossref
19.
Bisgaier  J, Rhodes  KV.  Auditing access to specialty care for children with public insurance.   N Engl J Med. 2011;364(24):2324-2333. doi:10.1056/NEJMsa1013285 PubMedGoogle ScholarCrossref
20.
Tipirneni  R, Rhodes  KV, Hayward  RA, Lichtenstein  RL, Reamer  EN, Davis  MM.  Primary care appointment availability for new Medicaid patients increased after Medicaid expansion in Michigan.   Health Aff (Millwood). 2015;34(8):1399-1406. doi:10.1377/hlthaff.2014.1425 PubMedGoogle ScholarCrossref
21.
Centers for Disease Control and Prevention. Provisional drug overdose death counts. Published 2018. Accessed October 5, 2018. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
22.
Kaiser Family Foundation. Status of state action on the Medicaid expansion decisions. Published July 1, 2020. Accessed July 14, 2020. https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/
23.
Patrick  SW, Buntin  MB, Martin  PR,  et al.  Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.   Subst Abus. 2019;40(3):356-362. doi:10.1080/08897077.2018.1488336PubMedGoogle ScholarCrossref
24.
Substance Abuse and Mental Health Services Administration. Buprenorphine practitioner locator. Accessed July 7, 2020. https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator
25.
Substance Abuse and Mental Health Services Administration. Opioid treatment program directory. Accessed July 7, 2020. https://dpt2.samhsa.gov/treatment/directory.aspx
26.
DRG; Decision Resources Group. Accessed October 15, 2018. https://decisionresourcesgroup.com/
27.
Hall  WJ, Chapman  MV, Lee  KM,  et al.  Implicit racial/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review.   Am J Public Health. 2015;105(12):e60-e76. doi:10.2105/AJPH.2015.302903 PubMedGoogle ScholarCrossref
28.
Substance Abuse and Mental Health Services Administration.  Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. US Department of Health and Human Services; 2016.
29.
Jones  HE, Kaltenbach  K, Heil  SH,  et al.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.   N Engl J Med. 2010;363(24):2320-2331. doi:10.1056/NEJMoa1005359 PubMedGoogle ScholarCrossref
30.
Sees  KL, Delucchi  KL, Masson  C,  et al.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.   JAMA. 2000;283(10):1303-1310. doi:10.1001/jama.283.10.1303 PubMedGoogle ScholarCrossref
31.
McCarthy  JJ, Leamon  MH, Parr  MS, Anania  B.  High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.   Am J Obstet Gynecol. 2005;193(3, pt 1):606-610. doi:10.1016/j.ajog.2005.03.072 PubMedGoogle ScholarCrossref
32.
Schwartz  RP, Kelly  SM, O’Grady  KE, Gandhi  D, Jaffe  JH.  Interim methadone treatment compared to standard methadone treatment: 4-month findings.   J Subst Abuse Treat. 2011;41(1):21-29. doi:10.1016/j.jsat.2011.01.008 PubMedGoogle ScholarCrossref
33.
Schwartz  RP, Kelly  SM, O’Grady  KE, Gandhi  D, Jaffe  JH.  Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.   Addiction. 2012;107(5):943-952. doi:10.1111/j.1360-0443.2011.03700.x PubMedGoogle ScholarCrossref
34.
Wilson  ME, Schwartz  RP, O’Grady  KE, Jaffe  JH.  Impact of interim methadone maintenance on HIV risk behaviors.   J Urban Health. 2010;87(4):586-591. doi:10.1007/s11524-010-9451-7 PubMedGoogle ScholarCrossref
35.
Schwartz  RP, Gryczynski  J, O’Grady  KE,  et al.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.   Am J Public Health. 2013;103(5):917-922. doi:10.2105/AJPH.2012.301049 PubMedGoogle ScholarCrossref
36.
Kandall  SR, Albin  S, Lowinson  J, Berle  B, Eidelman  AI, Gartner  LM.  Differential effects of maternal heroin and methadone use on birthweight.   Pediatrics. 1976;58(5):681-685.PubMedGoogle Scholar
37.
Young  JL, Martin  PR.  Treatment of opioid dependence in the setting of pregnancy.   Psychiatr Clin North Am. 2012;35(2):441-460. doi:10.1016/j.psc.2012.03.008 PubMedGoogle ScholarCrossref
38.
Dick  AW, Pacula  RL, Gordon  AJ,  et al.  Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11.   Health Aff (Millwood). 2015;34(6):1028-1034. doi:10.1377/hlthaff.2014.1205 PubMedGoogle ScholarCrossref
39.
Rosenblatt  RA, Andrilla  CH, Catlin  M, Larson  EH.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.   Ann Fam Med. 2015;13(1):23-26. doi:10.1370/afm.1735 PubMedGoogle ScholarCrossref
40.
Thomas  CP, Doyle  E, Kreiner  PW,  et al.  Prescribing patterns of buprenorphine waivered physicians.   Drug Alcohol Depend. 2017;181:213-218. doi:10.1016/j.drugalcdep.2017.10.002 PubMedGoogle ScholarCrossref
41.
Flavin  L, Malowney  M, Patel  NA,  et al.  Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the United States.   J Psychiatr Pract. 2020;26(1):17-22.PubMedGoogle Scholar
42.
Substance Abuse and Mental Health Services Administration. FindTreatment.gov. Accessed July 7, 2020. https://www.findtreatment.gov/
43.
Beetham  T, Saloner  B, Wakeman  SE, Gaye  M, Barnett  ML.  Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study.   Ann Intern Med. 2019;171(1):1-9. doi:10.7326/M18-3457 PubMedGoogle ScholarCrossref
44.
Bricker  J, Dettling  LJ, Henriques  A,  et al. Changes in U.S. family finances from 2013 to 2016: evidence from the Survey of Consumer Finances. Board of Governors of the Federal Reserve System; September 2017.
45.
Martin  PR, Finlayson  AJ.  Opioid use disorder during pregnancy in Tennessee: expediency vs. science.   Am J Drug Alcohol Abuse. 2015;41(5):367-370. doi:10.3109/00952990.2015.1047502 PubMedGoogle ScholarCrossref
46.
Medication-Assisted Treatment Program Licensing Act. S 1013. 2019 1st Special Session (West Virginia 2019).
47.
Guttmacher Institute. Substance use during pregnancy. Published 2018. Accessed March 8, 2018. https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy
48.
Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. HR 6, 115th Cong (2017-2018).
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Public Health
    August 14, 2020

    Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder

    Author Affiliations
    • 1Vanderbilt Center for Child Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
    • 2Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
    • 3Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
    • 4Department of Economics, Baylor University, Waco, Texas
    • 5Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
    • 6Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee
    • 7Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee
    • 8Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital and Northwestern University Feinberg School of Medicine, Chicago, Illinois
    • 9Network for Public Health Law, Los Angeles, California
    • 10Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee
    • 11RAND Corporation, Pittsburgh, Pennsylvania
    • 12Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
    JAMA Netw Open. 2020;3(8):e2013456. doi:10.1001/jamanetworkopen.2020.13456
    Key Points español 中文 (chinese)

    Question  Are pregnancy and insurance status associated with a woman’s ability to obtain an appointment with an opioid use disorder treatment clinician?

    Findings  In this cross-sectional study with random assignment of clinicians and simulated-patient callers, callers representing pregnant women were less likely than callers representing nonpregnant women to be granted an appointment with an opioid use disorder treatment clinician (61% vs 74%). There were substantial barriers for both pregnant and nonpregnant women attempting to gain access to treatment, including a large portion of clinicians who did not accept insurance and required cash payment for an appointment.

    Meaning  These findings suggest that pregnant and nonpregnant women face substantial barriers in obtaining appointments with an opioid use disorder treatment clinician.

    Abstract

    Importance  Medications for opioid use disorder, including buprenorphine hydrochloride and methadone hydrochloride, are highly effective at improving outcomes for individuals with the disorder. For pregnant women, use of these medications also improves pregnancy outcomes, including the risk of preterm birth. Despite the known benefits of medications for opioid use disorder, many pregnant and nonpregnant women with the disorder are not receiving them.

    Objective  To determine whether pregnancy and insurance status are associated with a woman’s ability to obtain an appointment with an opioid use disorder treatment clinician.

    Design, Setting, and Participants  In this cross-sectional study with random assignment of clinicians and simulated-patient callers (performed in “secret shopper” format), outpatient clinics that provide buprenorphine and methadone were randomly selected from publicly available treatment lists in 10 US states (selected for variability in opioid-related outcomes and policies) from March 7 to September 5, 2019. Pregnant vs nonpregnant woman and private vs public insurance assigned randomly to callers to create unique patient profiles. Simulated patients called the clinics posing as pregnant or nonpregnant women to obtain an initial appointment with a clinician.

    Main Outcomes and Measures  Appointment scheduling, wait time, and out-of-pocket costs.

    Results  A total of 10 871 unique patient profiles were assigned to 6324 clinicians. Among all women, 2312 of 3420 (67.6%) received an appointment with a clinician who prescribed buprenorphine, with lower rates among pregnant vs nonpregnant callers (1055 of 1718 [61.4%] vs 1257 of 1702 [73.9%]; relative risk, 0.83; 95% CI, 0.79-0.87). For clinicians who prescribed methadone, there was no difference in appointment access for pregnant vs nonpregnant callers (240 of 271 [88.6%] vs 237 of 265 [89.4%]; relative risk, 0.99; 95% CI, 0.93-1.05). Insurance was frequently not accepted, with 894 of 3420 buprenorphine-waivered prescribers (26.1%) and 174 of 536 opioid treatment programs (32.5%) granting appointments only when patients agreed to pay cash. Median wait times did not differ between pregnant and nonpregnant callers among buprenorphine prescribers (3 days [interquartile range, 1-7 days] vs 3 days [interquartile range, 1-7 days]; P = .43) but did differ among methadone prescribers (1 day [interquartile range, 1-4 days] vs 2 days [interquartile range, 1-6 days]; P = .049). For patients agreeing to pay cash, the median out-of-pocket costs for initial appointments were $250 (interquartile range, $155-$300) at buprenorphine prescribers and $34 (interquartile range, $15-$120) at methadone prescribers.

    Conclusions and Relevance  In this cross-sectional study with random assignment of clinicians and simulated-patient callers, many women, especially pregnant women, faced barriers to accessing treatment. Given the high out-of-pocket costs and lack of acceptance of insurance among many clinicians, access to affordable opioid use disorder treatment is a significant concern.

    ×